Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

296

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Non-Small Cell Lung Cancer
Head and Neck Cancer
Melanoma
Gastric Cancer
Renal Cell Carcinoma
Urothelial Carcinoma

Interventions

DRUG: INBRX-106 - Hexavalent OX40 agonist antibody
DRUG: pembrolizumab 200 mg
DRUG: pembrolizumab 400 mg
DRUG: Carboplatin AUC-5
DRUG: Carboplatin AUC-6
DRUG: Pemetrexed 500 mg/m2
DRUG: Cisplatin 75mg/m2
DRUG: Paclitaxel 200mg/m2
DRUG: Nab paclitaxel 100mg/m2

Sponsor

Inhibrx Biosciences, Inc

Collaborators

[object Object]